NCT02303990

RADVAX: A Stratified Phase I Trial of Pembrolizumab With Hypofractionated Radiotherapy in Patients With Advanced and Metastatic Cancers

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 59 (actual)
• Sponsor: Abramson Cancer Center at Penn Medicine · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Phase I clinical trial of hypofractionated radiotherapy to an isolated index lesion in combination with the PD-1 inhibitor, Pembrolizumab in patients with metastatic cancers who have failed anti-PD-1 therapy (melanoma and NSCLC) and patients with metastatic cancers who have have progressed after at least one regimen of systemic therapy (breast, pancreas, and other).

Conditions

• Metastatic Cancers

Interventions

Type	Name	Description
DRUG	Pembrolizumab
RADIATION	Radiotherapy

Timeline

• Start date: 2015-01-08
• Primary completion: 2018-12-01
• Completion: 2019-12-31
• First posted: 2014-12-01
• Last updated: 2021-05-12
• Results posted: 2021-04-22

Locations

1 site across 1 country: United States